PMDA Updates
PMDA Risk Communications
Revision of PRECAUTIONS
Pharmaceuticals and Medical Devices Safety Information
2nd PMDA Medical Devices Training Seminar
  • PMDA Updates
  • PMDA Risk Communications
  • Revisions of PRECAUTIONS
  • Pharmaceuticals and Medical Devices Safety Information
  • 2nd PMDA Medical Devices Training Seminar
2nd Medical Devices Training Seminar SEMINAR HIGHLIGHT DAY 1 DAY 2 DAY 3 DAY 4 DAY 5
What's NewRSS FeedsBack number
->February 27, 2015 new
PMDA Updates (February, 2015) posted
->February 27, 2015 new
PMDA Risk Communication: rebamipide, sitagliptin, triamcinolone acetonide, pazopanib, panitumumab, and cyclophosphamide posted
->February 26, 2015 new
The 3rd Meeting of the Subcommittee on Application of Numerical Analysis to Non-clnical Evaluation
->February 20, 2015
PDG Stage 4 draft; Propylene Glycol posted.
->February 17, 2015
Revisions of PRECAUTIONS : memantine, apixaban, montelukast, and telaprevir posted
->February 16, 2015
Investigation results: Lamictal (lamotrigine)
->February 13, 2015
The 4th Meeting of the CPC Subcommittee
->February 12, 2015
MHLW Pharmaceuticals and Medical Devices Safety Information posted: No 319, FY2014
->February 9, 2015
BLUE LETTER: Serious skin disorders suggestively caused by lamotrigine tablets, Case Report
->February 9, 2015
2nd PMDA Medical Devices Training Seminar: DAY 5 uploaded
->February 6, 2015
The Third Mid-term Targets and Mid-term Plan (FY2014-2018)
->February 6, 2015
2nd PMDA Medical Devices Training Seminar: DAY 4 uploaded
->February 5, 2015
2nd PMDA Medical Devices Training Seminar: DAY 3 uploaded
->February 5, 2015
The 3rd Meeting of the Subcommittee on Non-clinical Studies
->February 4, 2015
BLUE LETTER: Serious skin disorders suggestively caused by lamotrigine tablets
->February 4, 2015
2nd PMDA Medical Devices Training Seminar: DAY 2 uploaded
->February 3, 2015
2nd PMDA Medical Devices Training Seminar: DAY 1 uploaded
->February 2, 2015
Revisions of PRECAUTIONS: abiraterone acetate posted
->February 2, 2015
English translation of report: Summary of Discussion on the Assessment of the Current Status of Personalized Medicine Related to Development and Regulatory Review
->January 30, 2015
PMDA Updates (January, 2015) posted
->January 29, 2015
Executive Summary of Pharmaceuticals and Medical Devices Safety Information No 320, FY2014
->January 29, 2015
1st Malaysia-Japan Symposium
->January 23, 2015
PMDA Risk Communication: abiraterone, montelukast, telaprevir, memantine, and apixaban posted
->January 23, 2015
MHLW Pharmaceuticals and Medical Devices Safety Information posted: No 318, FY2014
->January 22, 2015
New drugs approvals: April - September 2014

>> Back number

International Programs

Implementation of PMDA International Strategic Plan through international regulatory harmonization, bilateral relationship, effective communication with relevant external parties, etc.

News and Reports
The Science Board

Framework to explore appropriate methods to evaluate medical products using advanced science and technology while exchanging opinions among academia and reviewers.

The Science Board The Science Board Subcommittees Outcome documents of the Science Board
Events / Symposia
Seminar
Past Presentations
Publications
Frequently Asked Questions (FAQ)
Services of PMDA
Drug and Medical Device Reviews

Scientific reviews and conformity audits of marketing authorization applications of drugs and medical devices, clinical trial consultations

Post-marketing Safety

Collection, analysis and dissemination of information related to the quality, efficacy and safety of pharmaceuticals and medical devices

Relief Services for Adverse Health Effects

Providing financial assistance for individuals affected by adverse drug reactions or infections from biological products